

**Remarks**

The present invention is directed to methods of treating a human with Alzheimer's disease. Claims 1-18 have been cancelled. Claims 21-27 have been added. Claims 19-27 are currently pending.

**Election of Species Requirement**

The claims are directed to methods for treating Alzheimer's disease by administering a supramolecular antigenic construct. The Examiner requires election of one species of modifier from the list recited in Claim 20, and one species of amyloid peptide from the list recited in Claim 25 for search purposes only.

As explained by the Examiner at page 3 of the Office Action, upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which depend from, or require all the limitations of an allowable generic claim.

In response to the election of species requirement, Applicants elect palmitic acid as the modifier, and Abeta<sub>1-16</sub> as the peptide with the understanding that the remaining species will be considered once allowable subject matter is found.

Currently claims 19, 20 and 22-27 are generic.

**Conclusions**

Applicants submit that the response herein provides a complete response to the Election of Species Requirement dated April 6, 2009.

If the Examiner believes there are other issues that may be resolved by telephone interview, or that there are any informalities remaining in the application that may be corrected by Examiner's Amendment, a telephone call to the undersigned is respectfully solicited.

No additional fees are believed due, however the Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment of fees to Deposit Account number 11-0980.

Respectfully submitted,

/Stephen C. MacDonald, Ph.D./  
Stephen C. MacDonald, Ph.D.  
Reg. No. 60,401

Date: June 1, 2008

King & Spalding LLP  
1180 Peachtree Street  
Atlanta, Georgia 30309-3521  
404-572-2715 (telephone)  
404-572-5135 (facsimile)